Valuation: Invion Limited

Market Cap 4.04M 2.84M 2.54M 2.34M 2.12M 3.97M 270M 28.21M 11.17M 141M 10.66M 10.44M 446M P/E 2025
-0.9x
P/E 2026 -0.56x
Enterprise Value 5M 3.51M 3.14M 2.9M 2.63M 4.91M 334M 34.88M 13.81M 175M 13.19M 12.91M 551M EV / Sales 2025
-
EV / Sales 2026 12.4x
Free-Float
58.97%
Yield 2025 *
-
Yield 2026 -
1 day+12.12%
1 week+8.82%
1 month-5.13%
3 months-17.78%
6 months-38.33%
Current year-60.22%
1 week 0.03
Extreme 0.032
0.04
1 month 0.03
Extreme 0.032
0.04
Current year 0.03
Extreme 0.032
0.1
1 year 0.03
Extreme 0.032
0.11
3 years 0.03
Extreme 0.032
0.8
5 years 0.03
Extreme 0.032
3.4
10 years 0.03
Extreme 0.032
5.8
Manager TitleAgeSince
Chief Executive Officer - 01/11/2020
Director of Finance/CFO 53 13/07/2020
Investor Relations Contact 54 -
Director TitleAgeSince
Chairman - 01/12/2017
Director/Board Member 76 12/02/2019
Director/Board Member 53 31/08/2024
Change 5-day change 1-year change 3-year change Capi.($)
+12.12%+8.82%-59.78%-92.60% 2.84M
+2.41%+0.29%+42.02%+71.57% 64.69B
-0.15%+7.50%+11.01%+73.48% 54.78B
+0.57%+4.60%+10.07%+92.86% 53.49B
+0.37%+4.67%+27.03%+52.07% 45.98B
-1.21%+2.32%+21.80%+123.81% 42.94B
-0.37%+5.07%+249.91%+918.74% 40.08B
+0.05%+0.21%+18.26%+58.53% 33.52B
-0.38%+5.68%+36.43%+27.54% 23.67B
+1.19%-4.98%+29.01%-0.65% 23.97B
Average +1.46%+3.05%+38.58%+132.53% 38.31B
Weighted average by Cap. +0.39%+2.73%+47.57%+158.57%

Financials

2025 2026
Net sales - 385K 271K 242K 223K 202K 378K 25.69M 2.69M 1.06M 13.46M 1.02M 994K 42.43M
Net income -8.81M -6.19M -5.53M -5.11M -4.63M -8.66M -588M -61.5M -24.35M -308M -23.25M -22.75M -971M -5.63M -3.96M -3.54M -3.27M -2.96M -5.54M -376M -39.33M -15.57M -197M -14.87M -14.55M -621M
Net Debt -850K -598K -534K -493K -447K -837K -56.78M -5.94M -2.35M -29.75M -2.24M -2.2M -93.79M 955K 672K 600K 554K 502K 940K 63.78M 6.67M 2.64M 33.42M 2.52M 2.47M 105M
Projected Income Statement - Annual - Invion Limited
Logo Invion Limited
Invion Limited is an Australia-based life science company. The Company is engaged in the research and development of Photosoft technology for the treatment of a range of cancers, atherosclerosis and infectious diseases. The Company is developing Photosoft technology as a Photodynamic Therapy (PDT). PDT uses non-toxic photosensitizers and light to selectively kill cancer cells and promote an anti-cancer immune response. PDT also offers an alternative treatment option aimed at achieving complete tumor regression and long-lasting remission. PDT has also demonstrated broad-spectrum activity across multiple infectious diseases, including bacteria, fungi and viruses. It holds the Australia and New Zealand license rights and distribution rights to Hong Kong and the rest of Asia Pacific, excluding China, Macau, Taiwan and Japan, to the Photosoft technology for all cancer indications. The Company’s wholly owned subsidiary is Epitech Dermal Science Pty Ltd.
Employees
4
Date Price Change Volume
23/10/26 A$0.0370 +12.12% 149,330
22/10/26 A$0.0330 +3.13% 157,500
21/10/26 A$0.0320 -11.11% 387,993
20/10/26 A$0.0360 -5.26% 305,623
19/10/26 A$0.0380 +11.76% 161,342